Barclays’s Tempest Therapeutics TPST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$246 Buy
+222
New +$366 ﹤0.01% 5085
2021
Q2
Sell
-219
Closed -$51K 5080
2021
Q1
$51K Sell
219
-2,162
-91% -$874K ﹤0.01% 4195
2020
Q4
$994K Buy
2,381
+1,858
+355% +$642K ﹤0.01% 2769
2020
Q3
$166K Buy
523
+51
+11% +$17.3K ﹤0.01% 3964
2020
Q2
$162K Buy
472
+149
+46% +$59.4K ﹤0.01% 4218
2020
Q1
$333K Buy
323
+275
+573% +$401K ﹤0.01% 3908
2019
Q4
$63K Buy
48
+24
+100% +$33.8K ﹤0.01% 5672
2019
Q3
$33K Sell
24
-7
-23% -$11.3K ﹤0.01% 6084
2019
Q2
$70K Buy
31
+23
+288% +$67.7K ﹤0.01% 5926
2019
Q1
$22K Buy
+8
New +$17.7K ﹤0.01% 6326
2018
Q4
Hold
0
7329
2018
Q3
Hold
0
7392
2018
Q2
Hold
0
7285
2018
Q1
Hold
0
7333
2017
Q4
Hold
0
7113
2017
Q3
Hold
0
7048
2017
Q2
Hold
0
6932
2017
Q1
Sell
-4
Closed -$18.6K 6632
2016
Q4
$19K Buy
+4
New +$49.8K ﹤0.01% 5653
2016
Q3
Hold
0
6084
2016
Q2
Hold
0
5989
2016
Q1
Sell
-1
Closed -$21.1K 5890
2015
Q4
$30K Sell
1
-15
-94% -$495K ﹤0.01% 5048
2015
Q3
$381K Buy
+16
New +$1.08M ﹤0.01% 3591
2015
Q2
Hold
0
5949
2015
Q1
Sell
-1
Closed -$133K 5738
2014
Q4
$82K Buy
+1
New +$73.2K ﹤0.01% 5358
2014
Q3
Hold
0
6952
2014
Q2
Hold
0
7415
2014
Q1
Hold
0
7340
2013
Q4
Hold
0
7373
2013
Q3
Hold
0
6939
2013
Q2
Hold
0
7311

Other funds holding TPST

Barclays's TPST Position: Q2 2026 in Review

Barclays opened a new position in Tempest Therapeutics (TPST) in Q2 2026: 222 shares worth $246. The stake represents ﹤0.01% of the portfolio and ranks #5085 among its holdings. This is a return to the name: Barclays previously reported a position in TPST as recently as Q1 2021.

Barclays first reported a position in TPST in Q4 2014 and has held it in 14 quarters since. The position peaked at $994K in Q4 2020. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Barclays held 222 shares of Tempest Therapeutics worth $246 as of Q2 2026.
  • Tempest Therapeutics was a new Barclays position in Q2 2026.
  • Tempest Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5085 holding.
  • Barclays first reported a position in Tempest Therapeutics in Q4 2014 and has held it in 14 quarters since.
  • Barclays's Tempest Therapeutics position peaked at $994K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.